May 25, 2016

Spartanburg Regional Healthcare System

Cutting-edge CyberKnife technology just got even more advanced for those undergoing treatment for prostate cancer. SpaceOAR improves outcomes and creates the safest environment for patients.
April 4, 2016

DOTmed – Augmenix announces publication of SpaceOAR pivotal clinical study results

Designed to act as a temporary spacer, the absorbable hydrogel pushes the rectum away from the prostate and reduces rectal radiation injury in men undergoing prostate cancer radiotherapy.
March 31, 2016

Business Wire – Augmenix Announces the Publication of the SpaceOAR® Hydrogel Pivotal Clinical Study Results: Application Technique and Patient Tolerance in Men Undergoing Prostate Cancer Radiotherapy

Using a minimally invasive procedure, SpaceOAR System is injected as a liquid into the space between the prostate and rectum where it expands the space and then solidifies into a soft hydrogel. The hydrogel remains stable for three months while protecting the rectum during radiotherapy, and then liquefies and is completely absorbed.
March 30, 2016

UroToday – Decision analysis model evaluating the cost of a temporary hydrogel rectal spacer before prostate radiation therapy to reduce the incidence of rectal complications.

We conducted a decision analysis to evaluate the cost effectiveness of a newly FDA approved rectal spacer gel (SpaceOAR) for the reduction of rectal toxicity of prostate radiation therapy (RT).
March 22, 2016

Business Wire – Florida Cancer Affiliates First in the State Certified to Offer New Spacing Device to Benefit Prostate Cancer Patients

“Providing the best possible treatment to patients is our top priority, which is why we are one of the first centers offering SpaceOAR hydrogel.”
March 15, 2016

Future of Radiation Health – What a New Breakthrough Means for Prostate Cancer Care

“In my opinion, the gel spacer is amongst the most important developments in radiation treatment of prostate cancer in the last several years.”
February 10, 2016

Dana-Farber/Brigham and Women’s Cancer Center – Innovative BWF Technique Preserves Rectal Tissue

Radiation Therapy for Prostate Cancer, Innovative BWH Technique Preserves Rectal Tissue.
January 5, 2016

Fox Carolina – Gibbs First in Carolinas with New Technology That Protects Men During Prostate Cancer Radiation Therapy

New SpaceOAR System provides more protection during radiation
January 4, 2016

ECRI Institute Invites Hospitals to Peek Behind the Curtain at the Top 10 Technological Advances to Watch in 2016

#9. Injected Bioabsorbable Hydrogel (SpaceOAR®): An End to Some Radiation Therapy Complications?

Please note that this article was researched and written by ECRI staff and some of the information is dated. There is an incorrect statement in the Cost Equation section “the company has not applied for a New Technology Add-on payment” Correct statement: The company applied for a New Tech APC in June 2015 and CMS issued a new code describing the procedure - C9743, injection/implantation of bulking or spacer material (any type) with or without image guidance, which became effective October 2015.
October 28, 2015

Augmenix Highlights Rapid U.S. Adoption of SpaceOAR System at ASTRO 2015

October 28, 2015 — Augmenix Inc. showcased the SpaceOAR System at the 57th annual American Society of Therapeutic Radiology and Oncology (ASTRO) meeting, highlighting robust commercial uptake in the United States. An absorbable hydrogel, SpaceOAR technology is designed to create space and protect the rectum in men undergoing prostate cancer radiotherapy. The device received clearance from the U.S. Food and Drug Administration (FDA) in April 2015 and since then, more than 40 cancer treatment centers in 19 states have adopted it [...]
October 19, 2015

SpaceOAR System Session presented at the Industry-Expert Theater – ASTRO 2015

Spacing Organs at Risk – SpaceOAR
Is it a game changer?
August 6, 2015

FDA Clears Hydrogel to Improve Prostate Radiotherapy Outcomes

Treatment temporarily expands space between prostate and rectum to reduce radiation dose to rectum April 6, 2015 — Augmenix Inc. announced U.S. Food and Drug Administration (FDA) clearance of the SpaceOAR System, cleared as a spacer to protect the rectum in men undergoing prostate cancer (PCa) radiotherapy. Despite many advancements in PCa radiotherapy, the close […]
June 30, 2015

Dr. Sylvester – WFLA

Download this video. SpaceOAR is used in beginning trials and this news coverage from WFLA, Channel 6 in Florida shows an interview with Dr. Sylvester.
April 8, 2015

CBS Local 8 News – Provision first proton therapy center using new product to benefit prostate cancer patients

KNOXVILLE, Tenn. (WVLT)– Provision Center for Proton Therapy is helping pioneer a new product that will help further protect prostate cancer patients from the effects of radiation therapy. Augmenix, Inc., privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy. In April, the U.S. Food and Drug Administration approved clearance of […]
April 3, 2015

NBC WKYC- New prostate treatment protects from radiation effects

The FDA approved a new product that protects prostate cancer patients from the side effects of radiation. CHARDON, Ohio — Two days ago, the FDA approved a new product that protects prostate cancer patients from the side effects of radiation. It’s called SpaceOAR (Space Organs At Risk) and it’s a hydrogel that is used as […]